TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.
Stocks · News reference
8-K filing — EXAGEN INC. (XGN)
Filed: 2026-08-04 AccNo: 0001274737-26-000047 Size: 330 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.
BTIG Maintains Buy on Exagen, Raises Price Target to $9
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.